The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

Leach, M. O., Brindle, K. M., Evelhoch, J. L., Griffiths, J. R., Horsman, M. R., Jackson, A., Jayson, G. C., Judson, I. R., Knopp, M. V., Maxwell, R. J., McIntyre, D., Padhani, A. R., Price, P., Rathbone, R., Rustin, G. J., Tofts, P. S., Tozer, G. M., Vennart, W., Waterton, J. C., Williams, S. R. and Workman, P. (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer, 92 (9). pp. 1599-610. ISSN 0007-0920 (Print)

Abstract

Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.

Actions (login required)